Format

Send to

Choose Destination
Cell Mol Life Sci. 2014 Oct;71(20):3885-901. doi: 10.1007/s00018-014-1656-6. Epub 2014 Jun 5.

Histone deacetylase inhibitors and cell death.

Author information

1
Department of Internal Medicine, Center for Autophagy Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Room Y9206C, Dallas, TX, 75390-9113, USA.

Abstract

Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.

PMID:
24898083
PMCID:
PMC4414051
DOI:
10.1007/s00018-014-1656-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center